

IT ALL STARTS HERE


GET YOUR PATIENTS STARTED ON JATENZO

JATENZO[®]
(testosterone undecanoate)
Capsules @

OUR PARTNER PHARMACIES ARE EQUIPPED TO HELP GET YOUR PATIENT THEIR JATENZO[®] PRESCRIPTION.

Commercially approved patients will receive their prescription for as little as **\$0***

If commercial insurance rejects coverage, your patient will pay \$150 for his therapy. If the patient does not have commercial insurance, he can purchase JATENZO for \$185.



National Pharmacies

Invictus Pharmacy

60 Essex St, Suite 202
Rochelle Park, NJ 07662

ePrescribing

NPI: 1073007340

NCPDP: 3155377

By Phone

Phone: 201-991-0800

Mon - Fri: 9am-5pm ET

Sat: 9am-3pm ET

Fax: 201-991-1980

Sterling Specialty Pharmacy

1312 Northland Dr, Suite 500
Mendota Heights, MN 55120

ePrescribing

NPI: 1225548480

NCPDP: 2433693

By Phone

Phone: 888-618-4126

Mon - Fri: 7:30am-5:30pm CT

Fax: 866-588-0371

Regional Pharmacies

Alabama

Village Discount Drugs

1001 Avalon Ave
Muscle Shoals, AL 35661

ePrescribing

NPI: 1154712685

NCPDP: 0140246

By Phone

Phone: 256-775-7455

Mon - Fri: 9am-6pm CT

Sat: 9am-1pm CT

Fax: 256-735-4431

California

ABC Pharmacy Laguna Hills

23141 Moulton Parkway, #107
Laguna Hills, CA 92653

ePrescribing

NPI: 1568814630

NCPDP: 5660659

By Phone

Phone: 949-916-9990

Mon - Fri: 9am-5pm PT

Fax: 949-377-0368



*See eligibility restrictions on page 2

Please see page 3 for Important Safety Information. Visit JatenzoHCP.com full Prescribing Information, including **BOXED WARNING**.



LEARN MORE
ABOUT OUR SUPPORT
AND RESOURCES

Scan this code with your phone camera

JATENZO®
(testosterone undecanoate)
Capsules @

Regional Pharmacies (continued)

Florida

SMP Pharmacy Solutions

7500 NW 26 St, Suite 101
Miami, FL 33122

ePrescribing

NPI: 1831481027
NCPDP: 5710365

By Phone

Phone: 305-740-9696
Mon - Fri: 9am-7pm ET
Sat - Sun: 10am-2pm ET
Fax: 305-740-9778

Texas

Choice Specialty Pharmacy

8850 Six Pines Dr, Ste 150
The Woodlands, Texas 77380

ePrescribing

NPI: 1841613981
NCPDP: 5910840

By Phone

Phone: 346-309-4800
Mon - Fri: 9am-5:30 pm CT
Fax: 832-616-3489

* TERMS, CONDITIONS & RESTRICTIONS

Eligible patients with commercial insurance will pay as little as \$0 for their monthly prescriptions, up to a maximum benefit amount applied per calendar year. Eligible patients without commercial insurance may still save up to 50% on their monthly prescription, up to a maximum benefit amount applied per calendar year. Offer valid for up to 12 uses. A valid Prescriber ID# is required on the prescription.

Patient Instructions: To redeem this offer, you must have a valid prescription for JATENZO. Follow the dosage instructions given by the doctor. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section below. Patients with questions about accessing the JATENZO Savings Card offer should ask their pharmacist to call the PDMI online processing Help Desk at 316-219-4802.

Pharmacist: When you apply this offer, you are certifying that you have not submitted a claim for reimbursement under any federal, state, or other governmental programs for this prescription. Participation in this program must comply with all applicable laws and regulations as a pharmacy provider. By participating in this program, you are certifying that you will comply with the terms and conditions described in the Restrictions section below.

Pharmacist Instructions for a Patient with an Eligible Third Party: Submit the claim to the primary Third-Party Payer first, then submit the balance due to PDMI as a Secondary Payer COB (coordination of benefits) with patient responsibility amount and a valid Other Coverage Code, (e.g., 8). The patient is responsible for as little as \$0 for their monthly prescriptions, up to a maximum benefit amount applied per calendar year. Offer valid for up to 12 uses. Reimbursement will be received from PDMI. Valid Other Coverage Code required. For any questions regarding PDMI online processing, please call the Help Desk at **316-219-4802**.

Restrictions: This offer is valid in the United States and Puerto Rico. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs). Cash Discount Cards and other noninsurance plans are not valid as primary under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. By using this offer, the patient certifies that he will comply with any terms of his health insurance contract requiring notification to his payer of the existence and/or value of this offer. Offer not valid for patients under 18 years of age. It is illegal to (or offer to) sell, purchase, or trade this offer. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Void where prohibited by law. Tolmar reserves the right to rescind, revoke, or amend this offer without notice at any time.

Please see page 3 for Important Safety Information. Visit JatenzoHCP.com full Prescribing Information, including **BOXED WARNING**.

INDICATION

JATENZO[®] (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

- Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

Limitation of use

Safety and efficacy of JATENZO in males less than 18 years old have not been established.

IMPORTANT SAFETY INFORMATION FOR JATENZO (testosterone undecanoate)

WARNING: INCREASES IN BLOOD PRESSURE

- **JATENZO can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death.**
- **Before initiating JATENZO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled.**
- **Periodically monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension and re-evaluate whether the benefits of JATENZO outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease on treatment.**
- **Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.**

CONTRAINDICATIONS

JATENZO is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate, in women who are pregnant, in men with a known hypersensitivity to JATENZO or its ingredients, or in men with hypogonadal conditions that are not associated with structural or genetic etiologies as JATENZO has not been established for these conditions and there is a risk of increased blood pressure with JATENZO that can increase the risk of MACE.

WARNINGS AND PRECAUTIONS

JATENZO can increase blood pressure, which can increase the risk of MACE, with greater risk in patients with established cardiovascular disease or risk factors for cardiovascular disease. Before initiating JATENZO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled. Monitor blood pressure approximately 3 weeks after initiating, increasing the dose, and periodically while on JATENZO, and treat any new or exacerbations of hypertension. Re-evaluate benefits and risks of continued treatment with JATENZO in patients who develop cardiovascular risk factors or disease. JATENZO is contraindicated in men with hypogonadal conditions such as "age-related hypogonadism" because the efficacy of JATENZO has not been established for these conditions and the increases in BP can increase the risk of MACE.

Polycythemia may require a lower dose or discontinuation of JATENZO. Check hematocrit prior to initiation and every 3 months while a patient is on JATENZO and if hematocrit becomes elevated, stop JATENZO until hematocrit decreases to an acceptable level. If hematocrit increases after JATENZO is restarted, stop permanently.

Some studies, but not all, have reported an increased risk of major adverse cardiovascular events (MACE) in association with use of testosterone replacement therapy in men. Long-term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. Patients should be informed of this possible risk when deciding whether to use or to continue to use JATENZO. JATENZO can increase blood pressure, which can increase the risk of MACE.

Important Safety Information (continued)

WARNINGS AND PRECAUTIONS (continued)

Monitor patients with benign prostatic hyperplasia (BPH) treated with androgens due to an increased risk for worsening signs and symptoms of BPH. Patients treated with androgens may be at increased risk for prostate cancer and should be evaluated prior to initiating and during treatment with androgens. Monitor prostate-specific antigen (PSA) levels periodically.

Postmarketing reports of venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported in patients using testosterone replacement products like JATENZO. Evaluate patients with signs or symptoms consistent with DVT or PE and, if a VTE is suspected, discontinue JATENZO and initiate appropriate workup and management.

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions. If abuse is suspected, check testosterone levels to ensure they are in therapeutic range. Counsel patients concerning the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.

JATENZO is not indicated for use in women.

Large doses of androgens can suppress spermatogenesis by feedback inhibition of pituitary FSH. Inform patients of this risk before prescribing JATENZO.

Prolonged use of high doses of methyltestosterone has been associated with serious hepatic adverse events. JATENZO is not known to cause these adverse events; however, patients should be instructed to report any signs of hepatic dysfunction and JATENZO should be discontinued while the cause is evaluated.

Androgens, including JATENZO, may promote retention of sodium and water. Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.

Gynecomastia may develop and persist in patients being treated for hypogonadism.

The treatment of hypogonadal men with testosterone may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease.

Changes in the serum lipid profile may require dose adjustment of lipid-lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically, particularly after starting testosterone therapy.

Use JATENZO with caution in cancer patients at risk of hypercalcemia. Monitor serum calcium concentration regularly during treatment with JATENZO in these patients.

Androgens, including JATENZO, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Depression and suicidal ideation have been reported in patients treated with JATENZO in clinical trials. Advise patients and caregivers to seek medical attention for manifestations of new-onset or worsening depression, suicidal ideation or behavior, anxiety, or other mood changes.

ADVERSE EVENTS

The most common adverse events of JATENZO (incidence $\geq 2\%$) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

DRUG INTERACTIONS

JATENZO can cause changes in insulin sensitivity or glycemic control. Androgens may decrease blood glucose and may require a decrease in the dose of antidiabetic medications.

Anticoagulant activity may be affected by androgens. More frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at initiation and termination of androgen therapy.

Please see additional Important Safety Information on next page. Visit JatenzoHCP.com full Prescribing Information, including BOXED WARNING.

JATENZO[®]
(testosterone undecanoate)
Capsules ©



DESIGNED TO HELP
GET MEN IN
THE ZONE.

THE JATENZONE[™]

DISCOVER MORE
ABOUT JATENZO



JatenzoHCP.com



Important Safety Information (continued)

DRUG INTERACTIONS (continued)

Use of testosterone and corticosteroids concurrently may increase fluid retention and requires monitoring in patients with cardiac, renal, or hepatic disease.

Some prescription and nonprescription analgesic cold medications contain drugs known to increase blood pressure and concomitant use of these medications with JATENZO may lead to additional increases in blood pressure.

Anticoagulant activity may be affected by androgens. More frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at initiation and termination of androgen therapy.

Use of testosterone and corticosteroids concurrently may increase fluid retention and requires monitoring in patients with cardiac, renal, or hepatic disease.

Some prescription and nonprescription analgesic cold medications contain drugs known to increase blood pressure and concomitant use of these medications with JATENZO may lead to additional increases in blood pressure.

USE IN SPECIFIC POPULATIONS

The safety and efficacy of JATENZO in pediatric patients less than 18 years old have not been established. Improper use may result in acceleration of bone age and premature closure of epiphyses.

There have not been sufficient numbers of geriatric patients involved in controlled clinical studies utilizing JATENZO to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. There is insufficient long-term safety data in geriatric patients utilizing JATENZO to assess the potentially increased risk of cardiovascular disease and prostate cancer.

Please visit JatenzoHCP.com for full Prescribing Information, including **BOXED WARNING**.